Trusted Talent Partner For Life Sciences

Supporting Pharma, TechBio, CROs and Biotech to build world class teams in Drug Discovery,  AI/ML and Computational Sciences

Talent Partners for
Human Health Experts

 We provide Talent and Consultancy services for
Drug and Target Discovery and Computational Sciences globally.

Building teams in:

Icon Slider

Bioinformatics

Data Science

Computational Biology

Drug Discovery

Target Identification

Computational Chemistry

Artificial Intelligence

Medicinal Chemistry

Synthetic Biology

Software Development

Business Development

Bioinformatics

Data Science

Computational Biology

Drug Discovery

Target Identification

Computational Chemistry

Artificial Intelligence

Medicinal Chemistry

Synthetic Biology

Software Development

Business Development

Why choose KEMIO Consulting?

We are a multilingual team of like-minded individuals who are passionate about improving human health through our consulting and partnerships.

 

  • 95% fill rate on exclusive and retained vacancies
  • 1.64 : 1 applicant-to-interview ratio
  • 24-hour response rate
  • 30,000+ candidates in our global network
  • 24-hour vacancy activation rate
  • 3 decades of life sciences recruitment experience

Supporting biotechnology, pharmaceutical, and research partners across the UK, Europe & North America

Why choose KEMIO Consulting?

We are a multilingual team of like-minded individuals who are passionate about improving human health through our consulting and partnerships.

  • 95% fill rate on exclusive and retained vacancies
  • 1.64 : 1 applicant-to-interview ratio
  • 24-hour response rate
  • 30,000+ candidates in our global network
  • 24-hour vacancy activation rate 
  • 3 decades of life sciences recruitment experience

Supporting biotechnology, pharmaceutical, and research partners across the UK, Europe & North America

What people say about KEMIO

Insights

AI-fluent leadership is showing up in the shortlist.

One under-discussed shift in 2026: While parts of the labour market feel tight, executive-level movement is staying active — and AI-fluent leadership is showing up more often in the shortlist. [...]

Review of JPM 2026 – Nvidia & Lilly Deal

Nvidia–Lilly: a $1B reminder that compute is becoming a strategic supply chain   The most emblematic AI announcement at JPM wasn’t a new foundation model paper. It was infrastructure: Eli [...]

Review of JPM 2026 – AI as Plumbing

The vibe shift: from “AI as differentiator” to “AI as plumbing”   A useful way to interpret JPM 2026 is this: the market is pricing AI like electricity, not like [...]

Follow us on

Contact Us

.